Search research articles
Contact Us
Filters
Showing results (141-150 of 312) with videos related to
Page
of 32
Sort By:
JCO Precision Oncology
|
September 15, 2022
Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer
Edward D Esplin, Sarah M Nielsen, Sara L Bristow, et al.
Future Oncology (London, England)
|
April 1, 2025
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients
Rana R McKay, Ashley E Ross, Mark A Preston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 18, 2018
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer
Shilpa Gupta, Luke T Nordquist, Mark T Fleming, et al.
Cancers
|
October 14, 2023
Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer
Fred Saad, Daniel J George, Michael S Cookson, et al.
Urology Practice
|
August 18, 2023
The Need for Survivorship Care in Genitourinary Cancers: Considerations from SUO and LUGPA
Hamed Ahmadi, Michael A S Jewett, Neal D Shore, et al.
BJU International
|
September 10, 2022
Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial
Neal D Shore, Arnulf Stenzl, Christopher Pieczonka, et al.
Reviews in Urology
|
November 27, 2019
Preserving Independent Urology: LUGPA's First Decade
Neal D Shore, Deepak A Kapoor, Evan R Goldfischer, et al.
The Journal of Urology
|
April 10, 2018
The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer
Charles J Ryan, E David Crawford, Neal D Shore, et al.
The Journal of Urology
|
February 9, 2023
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial
Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2016
Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents
Allan Lipton, Matthew R Smith, Karim Fizazi, et al.
Page
of 32
Search research articles
Search
Showing results (141-150 of 312) with videos related to
Sort By:
Page
of 32
JCO Precision Oncology
|
September 15, 2022
Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer
Edward D Esplin, Sarah M Nielsen, Sara L Bristow, et al.
Future Oncology (London, England)
|
April 1, 2025
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients
Rana R McKay, Ashley E Ross, Mark A Preston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 18, 2018
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer
Shilpa Gupta, Luke T Nordquist, Mark T Fleming, et al.
Cancers
|
October 14, 2023
Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer
Fred Saad, Daniel J George, Michael S Cookson, et al.
Urology Practice
|
August 18, 2023
The Need for Survivorship Care in Genitourinary Cancers: Considerations from SUO and LUGPA
Hamed Ahmadi, Michael A S Jewett, Neal D Shore, et al.
BJU International
|
September 10, 2022
Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial
Neal D Shore, Arnulf Stenzl, Christopher Pieczonka, et al.
Reviews in Urology
|
November 27, 2019
Preserving Independent Urology: LUGPA's First Decade
Neal D Shore, Deepak A Kapoor, Evan R Goldfischer, et al.
The Journal of Urology
|
April 10, 2018
The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer
Charles J Ryan, E David Crawford, Neal D Shore, et al.
The Journal of Urology
|
February 9, 2023
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial
Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2016
Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents
Allan Lipton, Matthew R Smith, Karim Fizazi, et al.
Page
of 32